Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes

Myelofibrosis (MF) is a clonal disorder of hematopoiesis and the most aggressive subtype among classical BCR::ABL1 negative myeloproliferative neoplasms (MPN). Approximately 90% of patients harbor a mutation affecting JAK2, MPL, or CALR signaling which results in constitutive activation of the JAK/STAT pathway and culminates in proliferative and dysfunctional blood cell production, extramedullary hematopoiesis, and constitutional symptoms. Conversely, 5-10% of patients are deemed to be “triple-negative” (TN), a designation associated with poor prognosis (1).

Source: Clinical Lymphoma, Myeloma and Leukemia - March 10, 2024 Category: Hematology Authors: Luis E. Aguirre, Akriti Jain, Somedeb Ball, Najla Al Ali, Virginia O. Volpe, Sara Tinsley-Vance, David Sallman, Kendra Sweet, Jeffrey Lancet, Eric Padron, Seongseok Yun, Andrew Kuykendall, Rami Komrokji Tags: Original Study Source Type: research